The Beneficiaries of GLP-1 Drugs Across Industries Health Insurers and the Cost of Obesity Source: McKinsey 4 Although weight loss has been the main focus in the analyses of these drugs so far, it is important to bear in mind that with them comes the improvement in other measurements of health, such as blood glucose levels, cardiovascular parameters, cholesterol and triglyceride levels
Most or all of these are common in women who are overweight: Ultra-processed foods Low fiber intake Low protein diets Imbalanced gut flora Lack of short-chain fatty acids Chronic inflammation Poor quality sleep Chronic stress or high cortisol Obesity Insulin resistance/prediabetes Poor vagal nerve function Aging The critical point here is that all but one of those factors are largely or totally within our control
P., Ajabiya, J., Teli, D., Bojarska, J., & Apostolopoulos, V
It was showed that a GLP-1 analogue with improved half-life in a NEP 24.11 degradation assay had prolonged action in mice, therefore making this assay relevant to evaluate the potential efficacy in vivo of our compounds 40
If millions more people want to start taking a GLP-1, the clinics are going to be busy, Weber said
Totals stay visible before payment
